CD24 and glioblastoma: We further propose that the local application of the anti‐CD47/anti‐CD24 antibodies, combined with CAR‐T, tumor vaccines, immune checkpoint inhibitors, or other systemic immunotherapies will likely improve the overall efficacy for clinical treatment of glioblastoma (Figure 3).